# Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

> **NCT03587207** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 520 (actual)

## Conditions studied

- Meningitis, Meningococcal

## Interventions

- **BIOLOGICAL:** MenABCWY vaccine
- **BIOLOGICAL:** rMenB+OMV NZ (Bexsero) vaccine
- **BIOLOGICAL:** MenACWY (Menveo) vaccine

## Key facts

- **NCT ID:** NCT03587207
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2018-12-19
- **Final completion:** 2018-12-19
- **Target enrollment:** 520 (ACTUAL)
- **Last updated:** 2020-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03587207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03587207, "Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03587207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*